JP2007516193A - クエチアピンの代謝産物 - Google Patents
クエチアピンの代謝産物 Download PDFInfo
- Publication number
- JP2007516193A JP2007516193A JP2006518324A JP2006518324A JP2007516193A JP 2007516193 A JP2007516193 A JP 2007516193A JP 2006518324 A JP2006518324 A JP 2006518324A JP 2006518324 A JP2006518324 A JP 2006518324A JP 2007516193 A JP2007516193 A JP 2007516193A
- Authority
- JP
- Japan
- Prior art keywords
- symptoms
- bipolar
- depression
- disorder
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- JLOAJISUHPIQOX-UHFFFAOYSA-N C(C1)NCCN1C1=Nc2ccccc2Sc2ccccc12 Chemical compound C(C1)NCCN1C1=Nc2ccccc2Sc2ccccc12 JLOAJISUHPIQOX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【化1】
Description
11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピンの製造
11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン・二塩酸塩の製造
遊離塩基を、メタノール(125ml)及びジエチルエーテル(125ml)の混合物に溶解し、次いで1.0M−HCl/エーテル(Aldrich Inc.)250mlで処理することによって、その二塩酸塩に変換した。最初、灰色を帯びた白色粘着性の固体が分離し、そして混合物を更にエーテル500mlで希釈した。粘着性の固体は、撹拌を延長しても固体化しなかった。溶媒を粘性物質からデカントして除いた。粘性物質を無水エタノール(200ml)で処理し、次いで、結晶が生じるまで撹拌し、結晶の濃厚な白色懸濁液を得た。この混合物をエーテル(800ml)でゆっくり希釈し、結晶化が完了するまで一夜撹拌放置した。二塩酸塩を濾過により単離し、エーテルで洗浄(3×50ml)し、次いで60℃で減圧乾燥し、標題化合物の二塩酸塩を白色固体(31.64g、変換率98.8%)として得た。
分析:
生成物は、NMR及びLC/MS(300MHz、CDCl3;AP+、M+1=296.4)により特性決定した。
マウスでのアッセイ
ドーパミン拮抗性の評価を齧歯類モデルで行った。使用した方法及び手順は、J. Med. Chem., 44(3), 372-389, 2001に見出すことができ、この文献は参照することによって本明細書の一部に取り入れられている。結果は以下の通りである。脳セロトニン5−HT2受容体に対する結合親和性は、27K1nM、ドーパミンD1及びD2受容体に対する結合親和性は、それぞれ、1489及び234K1nMであった。これらの結果は、二塩酸塩としての本発明の化合物が広範囲な神経伝達物質受容体と相互に作用することを示すが、しかしながら、二塩酸塩としての本発明の化合物は、又、脳においてドーパミン(D2)受容体と比較してセロトニン(5−HT2)受容体に対して、より高い親和性を有していることを明らかにしている。セロトニン及びドーパミン受容体拮抗作用の組合せにおいて、D2受容体よりも5−HT2受容体に対して高い親和性を有するということは、式Iの化合物が強力な非定型抗精神病薬であることを示唆している。J. Goldstein, Quetiapine Fumarate (Seroquel): a new atypical antipsychotic, 35(3) Drugs of Today 193-210(1999).
Claims (11)
- 化合物名11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピンを有する有効量の化合物、又は医薬として許容されるその塩を哺乳動物に投与することを含む、統合失調症、痴呆、不安、うつ病、気分障害、双極性障害、双極性躁病、双極性うつ病、認識力障害、精神病及び神経変性障害に関連する症状又は状態の少なくとも一つを治療する方法。
- 症状又は状態が、不安、激越、敵意、パニック、摂食障害、情動症状、気分症状、陰性精神症状及び陽性精神症状を含む、請求項1に記載の方法。
- 医薬として許容される塩が二塩酸塩である、請求項1に記載の方法。
- 有効量の第1成分の11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン又は医薬として許容されるその塩を、1種又はそれ以上の別の治療活性剤、ベンゾジアゼピン、5−HT1Aリガンド、5−HT1Bリガンド、5−HT1Dリガンド、mGluR2Aアゴニスト、mGluR5アンタゴニスト、抗精神病薬、NK1受容体アンタゴニスト、抗うつ剤又はセロトニン再取り込み阻害剤から選択される有効量の第2成分と組合せて投与することを含む、統合失調症、痴呆、不安、うつ病、気分障害、双極性障害、双極性躁病、双極性うつ病、認識力障害、精神病及び神経変性障害に関連する症状又は状態の少なくとも一つを治療する方法。
- 有効量の11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン又は医薬として許容されるその塩を哺乳動物に投与することを含む、統合失調症、痴呆、不安、うつ病、気分障害、双極性障害、双極性躁病、双極性うつ病、認識力障害、精神病、神経変性障害、激越、敵意、パニック、摂食障害、情動症状、気分症状、陰性精神症状及び陽性精神症状の治療における11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン又は医薬として許容されるその塩の使用。
- 医薬として許容される塩が二塩酸塩である、請求項5に記載の組成物。
- 請求項5に記載の有効量の医薬組成物を哺乳動物に投与することを含む、統合失調症、痴呆、不安、うつ病、気分障害、双極性障害、双極性躁病、双極性うつ病、認識力障害、精神病、神経変性障害に関連する症状又は状態の少なくとも一つを治療する方法。
- 症状又は状態が、不安、激越、敵意、パニック、摂食障害、情動症状、気分症状、陰性精神症状及び陽性精神症状を含む、請求項8に記載の方法。
- 哺乳動物における統合失調症、痴呆、不安、うつ病、気分障害、双極性障害、双極性躁病、双極性うつ病、認識力障害、精神病、神経変性障害、不安、激越、敵意、パニック、摂食障害、情動症状、気分症状、陰性精神症状及び陽性精神症状の治療用医薬の製造における、請求項5に記載の医薬組成物の使用。
- 哺乳動物における統合失調症、痴呆、不安、うつ病、気分障害、双極性障害、双極性躁病、双極性うつ病、認識力障害、精神病、神経変性障害、不安、激越、敵意、パニック、摂食障害、情動症状、気分症状、陰性精神症状及び陽性精神症状の治療用医薬の製造における、11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピンの使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48436503P | 2003-07-02 | 2003-07-02 | |
PCT/GB2004/002783 WO2005002586A1 (en) | 2003-07-02 | 2004-06-28 | Metabolite of quetiapine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007516193A true JP2007516193A (ja) | 2007-06-21 |
JP2007516193A5 JP2007516193A5 (ja) | 2007-08-16 |
Family
ID=33563981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006518324A Ceased JP2007516193A (ja) | 2003-07-02 | 2004-06-28 | クエチアピンの代謝産物 |
Country Status (20)
Country | Link |
---|---|
US (1) | US20050026900A1 (ja) |
EP (1) | EP1644005B1 (ja) |
JP (1) | JP2007516193A (ja) |
KR (1) | KR20060082037A (ja) |
CN (1) | CN1816339B (ja) |
AR (1) | AR045004A1 (ja) |
AT (1) | ATE477803T1 (ja) |
AU (1) | AU2004253334A1 (ja) |
BR (1) | BRPI0412127A (ja) |
CA (1) | CA2531284A1 (ja) |
DE (1) | DE602004028739D1 (ja) |
ES (1) | ES2349091T3 (ja) |
IL (1) | IL172616A0 (ja) |
IS (1) | IS8283A (ja) |
MX (1) | MXPA05013869A (ja) |
NO (1) | NO20060556L (ja) |
RU (1) | RU2005141060A (ja) |
TW (1) | TW200509944A (ja) |
UY (1) | UY28400A1 (ja) |
WO (1) | WO2005002586A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL164155A0 (en) * | 2002-03-20 | 2005-12-18 | Teva Pharma | Crystalline forms of quetiapine hemifumarate |
WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
EP1838325A1 (en) * | 2005-01-07 | 2007-10-03 | AstraZeneca AB | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
US20060252744A1 (en) * | 2005-04-04 | 2006-11-09 | Burstein Ethan S | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
WO2006113425A1 (en) * | 2005-04-14 | 2006-10-26 | Teva Pharmaceutical Industries Ltd. | Process for preparing quetiapine fumarate |
WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
WO2008079839A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab | Compounds and uses thereof |
US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
WO2008079848A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab (Se/Se) | Compounds and uses thereof |
WO2007062337A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Crystalline forms |
US20090069292A1 (en) * | 2005-11-18 | 2009-03-12 | Astrazeneca Ab | Liquid Formulations |
CN101360725B (zh) * | 2005-11-18 | 2011-09-21 | 阿斯利康公司 | 固体制剂 |
WO2008079838A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab | Compounds and uses thereof |
WO2007062336A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Salt forms |
WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
US20100093700A1 (en) * | 2007-03-22 | 2010-04-15 | Astrazeneca Ab | Methods of Treating Mood Disorders |
CN102781236B (zh) | 2009-12-31 | 2015-01-07 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
DK2544536T3 (en) | 2010-03-11 | 2019-02-04 | Kempharm Inc | FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT |
CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US3663696A (en) * | 1966-05-20 | 1972-05-16 | American Cyanamid Co | Treatment of depression with 2-chloro-11 - (piperazinyl)dibenz - (b,f)(1,4)oxazepines and acid addition salts thereof |
US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US5661184A (en) * | 1994-08-12 | 1997-08-26 | Eli Lilly And Company | Psychiatric agents |
AU5489299A (en) * | 1998-08-18 | 2000-03-14 | Sepracor, Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
AU2004206931A1 (en) * | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
-
2004
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Application Discontinuation
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 EP EP04743131A patent/EP1644005B1/en not_active Expired - Lifetime
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en active Search and Examination
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3663696A (en) * | 1966-05-20 | 1972-05-16 | American Cyanamid Co | Treatment of depression with 2-chloro-11 - (piperazinyl)dibenz - (b,f)(1,4)oxazepines and acid addition salts thereof |
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
Also Published As
Publication number | Publication date |
---|---|
EP1644005B1 (en) | 2010-08-18 |
IL172616A0 (en) | 2006-04-10 |
MXPA05013869A (es) | 2006-02-28 |
US20050026900A1 (en) | 2005-02-03 |
IS8283A (is) | 2006-02-01 |
RU2005141060A (ru) | 2006-07-27 |
AU2004253334A1 (en) | 2005-01-13 |
ATE477803T1 (de) | 2010-09-15 |
WO2005002586A8 (en) | 2006-02-09 |
UY28400A1 (es) | 2005-01-31 |
CN1816339A (zh) | 2006-08-09 |
DE602004028739D1 (de) | 2010-09-30 |
CA2531284A1 (en) | 2005-01-13 |
BRPI0412127A (pt) | 2006-08-15 |
WO2005002586A1 (en) | 2005-01-13 |
AR045004A1 (es) | 2005-10-12 |
KR20060082037A (ko) | 2006-07-14 |
NO20060556L (no) | 2006-04-03 |
ES2349091T3 (es) | 2010-12-27 |
EP1644005A1 (en) | 2006-04-12 |
TW200509944A (en) | 2005-03-16 |
CN1816339B (zh) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007516193A (ja) | クエチアピンの代謝産物 | |
ES2670568T3 (es) | 8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina, sus sales, solvatos o hidratos y su uso para el tratamiento de trastornos del SNC | |
JP2008525414A (ja) | 精神病性障害を治療するためのサブコメリンと神経遮断薬との組み合わせ | |
IL172334A (en) | Benzazepine Derivatives, Pharmaceutical Preparation, Method of Manufacturing Pharmaceutical Preparation, Use of Pharmaceutical Manufacture Derivatives | |
KR20010014279A (ko) | 뮤 오피오이드 화합물의 호흡 저하 및 수반되는 부작용을감소시키기 위한 조성물 및 그 방법 | |
HU201062B (en) | Process for producing thiazepine derivatives and pharmaceutical compositions containing them | |
JPH09501156A (ja) | 治療法で使用するピペラジン化合物 | |
JP2003519675A (ja) | シブトラミンのラセミ型又は光学的に純粋な代謝産物、それらの調製、それらを含有する組成物及びそれらのドーパミン再取込みインヒビターとしての使用 | |
US20110136786A1 (en) | Method of treating mood disorders | |
US20110144089A1 (en) | Method of treating schizophrenia and other disorders | |
KR20050121235A (ko) | 정동 장애를 치료하기 위한10-히드록시-10,11-디히드로카르바마제핀 유도체의 용도 | |
US20110136784A1 (en) | Method of Treating Anxiety Disorders | |
JP2008526839A (ja) | 11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 | |
US20050026899A1 (en) | Metabolite | |
JP2009516706A (ja) | 結晶形 | |
US20090093461A1 (en) | Methods of Treating Anxiety and Mood Disorders | |
US20090093460A1 (en) | Compositions | |
US20100093700A1 (en) | Methods of Treating Mood Disorders | |
US20110144088A1 (en) | Method of treating sleep disorders | |
US20110136785A1 (en) | Method of treatment | |
JP2009516705A (ja) | 塩の形態 | |
US20130203789A1 (en) | Novel Inhibitors of LYN Kinase and Methods Using Same | |
EP1307463A1 (en) | Pyrrolo 2,1-b]-[1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | |
US20060229292A1 (en) | Method of treating childhood disorders | |
AU2001284391A1 (en) | Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070628 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100817 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110217 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110524 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20140422 |